Lexeo Therapeutics, Inc. Common Stock (LXEO) vs Upstream Bio, Inc. (UPB)
A side-by-side comparison of Lexeo Therapeutics, Inc. Common Stock and Upstream Bio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
LXEO
Lexeo Therapeutics, Inc. Common Stock
$3.30HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
UPB
Upstream Bio, Inc.
$4.59HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — LXEO vs UPB
growth of $100 · dividends reinvested · last 2yLXEO -58.4% (-35.5%/yr)UPB -78.0% (-53.0%/yr)LXEO compounded faster over this window
LXEO UPB
LXEO vs UPB: by the numbers
- •LXEO is the larger company ($259M vs $250M market cap).
- •Both run net losses; LXEO's is the smaller (0.00% vs -4955.67% net margin).
Metrics side by side
Valuation
| Metric | LXEO | UPB |
|---|---|---|
| P/S ratio | N/A | 79.10 |
| P/B ratio | 1.10 | 0.92 |
Profitability
| Metric | LXEO | UPB |
|---|---|---|
| Gross margin | 0.00% | 98.45% |
| Operating margin | 0.00% | -5618.82% |
| Net margin | 0.00% | -4955.67% |
| ROE | -37.12% | -57.76% |
| ROIC | -39.76% | -62.51% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.